Mechanisms of the development of androgen independence in prostate cancer

The effectiveness of androgen ablation in the management of advanced prostate cancer is of limited duration, with the median length of response being only 18–24 months. The transition of the prostate cancer cell to an androgen independent phenotype is a complex process that involves selection and outgrowth of pre-existing clones of androgen-independent cells (clonal selection) as well as adaptive up-regulation of genes that help the cancer cells survive and grow after androgen ablation (adaptation). These two mechanisms share an important pre-requisite characteristic: prostate cancers are heterogeneous tumours comprised of various subpopulations of cells that respond differently to androgen withdrawal therapy. This tumour heterogeneity may reflect either a multifocal origin, adaptation to environmental stimuli, and/or genetic instability of the initial cancer. This review will reexamine the different mechanisms that enable prostate cancer cells to proliferate in an androgen depleted environment.

[1]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[2]  M. Gleave,et al.  Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy , 2002, The Prostate.

[3]  M. Wilson,et al.  Clusterin is a secreted mammalian chaperone. , 2000, Trends in biochemical sciences.

[4]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. , 1994, Cancer research.

[5]  J. Manola,et al.  Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.

[6]  J. Carver,et al.  Clusterin Has Chaperone-like Activity Similar to That of Small Heat Shock Proteins* , 1999, The Journal of Biological Chemistry.

[7]  A. Klippel,et al.  Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt , 1997, Molecular and cellular biology.

[8]  H. Miyake,et al.  Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. , 2000, Cancer research.

[9]  A Rostagno,et al.  Apolipoprotein J (clusterin) and Alzheimer's disease , 2000, Microscopy research and technique.

[10]  B. Calabretta,et al.  Direct Transactivation of the Anti-apoptotic Gene Apolipoprotein J (Clusterin) by B-MYB* , 2000, The Journal of Biological Chemistry.

[11]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[12]  C. Pilarsky,et al.  Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas , 2005, Journal of Cancer Research and Clinical Oncology.

[13]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[14]  M. Gleave,et al.  Dysregulation of Sterol Response Element-Binding Proteins and Downstream Effectors in Prostate Cancer during Progression to Androgen Independence , 2004, Cancer Research.

[15]  T. Tammela,et al.  Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. , 2000, The Journal of urology.

[16]  M. Gleave,et al.  Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. , 2003, Oncology reports.

[17]  O. Halvorsen,et al.  Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  K. Grigor,et al.  Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer , 2003, British Journal of Cancer.

[19]  T. H. van der Kwast,et al.  Androgen‐independent growth is induced by neuropeptides in human prostate cancer cell lines , 2000, The Prostate.

[20]  I. Leav,et al.  Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat. , 1998, The American journal of pathology.

[21]  J. Lloreta,et al.  Her-2/neu Expression in Prostate Cancer , 2004, Clinical Cancer Research.

[22]  M. Gleave,et al.  Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway. , 2000, Endocrinology.

[23]  H. Klocker,et al.  Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.

[24]  K. Akakura,et al.  Codon 877 Mutation in the Androgen Receptor Gene in Advanced Prostate Cancer: Relation to Antiandrogen Withdrawal Syndrome , 1996, The Prostate.

[25]  D. Peehl,et al.  The IGF axis in the prostate. , 1994, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[26]  A. Belldegrun,et al.  Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. , 1999, Cancer research.

[27]  E. Jaffe,et al.  Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. , 2000, Blood.

[28]  R. Herbst,et al.  Oblimersen Sodium (Genasense bcl-2 Antisense Oligonucleotide) , 2004, Clinical Cancer Research.

[29]  A. Benabid,et al.  Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Gleave,et al.  Heat Shock Protein 27 Increases after Androgen Ablation and Plays a Cytoprotective Role in Hormone-Refractory Prostate Cancer , 2004, Cancer Research.

[31]  K. Makino,et al.  HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. , 2000, Cancer research.

[32]  W. Kelly.  Endocrine Withdrawal Syndrome and Its Relevance to the Management of Hormone Refractory Prostate Cancer , 1998, European Urology.

[33]  G. Bubley,et al.  Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  E. Small,et al.  Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.

[35]  N. Bruchovsky,et al.  Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways* , 2002, The Journal of Biological Chemistry.

[36]  W. Isaacs,et al.  Androgen receptor gene mutations in human prostate cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[37]  P. Cohen,et al.  Role of insulin‐like growth factors and their binding proteins in growth control and carcinogenesis , 2000, Journal of cellular physiology.

[38]  M. Gleave,et al.  Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl‐2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model , 2001, International journal of cancer.

[39]  J. Isaacs,et al.  The biology of hormone refractory prostate cancer. Why does it develop? , 1999, The Urologic clinics of North America.

[40]  M. C. Hu,et al.  HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. , 2000, The Journal of biological chemistry.

[41]  F. S. French,et al.  Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. , 2001, Cancer research.

[42]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[43]  M E Rosenberg,et al.  Clusterin: physiologic and pathophysiologic considerations. , 1995, The international journal of biochemistry & cell biology.

[44]  J. Schleutker,et al.  Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  L. Hakansson,et al.  Bcl-2 expression in metastatic malignant melanoma. Importance for the therapeutic efficacy of biochemotherapy , 2003, Cancer Immunology, Immunotherapy.

[46]  R L Vessella,et al.  Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .

[47]  T. McDonnell,et al.  Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. , 1997, The Journal of urology.

[48]  Donna M. Peehl,et al.  Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor , 2000, Nature Medicine.

[49]  L. French,et al.  Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus. , 1992, The Journal of clinical investigation.

[50]  M. Hung,et al.  HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway* , 2000, The Journal of Biological Chemistry.

[51]  R. Roth,et al.  Modulation of Insulin Receptor Substrate-1 Tyrosine Phosphorylation by an Akt/Phosphatidylinositol 3-Kinase Pathway* , 1999, The Journal of Biological Chemistry.

[52]  M. Gleave,et al.  Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. , 2000, Cancer research.

[53]  M. Gleave,et al.  Inhibition of progression to androgen‐independence by combined adjuvant treatment with antisense BCL‐XL and antisense Bcl‐2 oligonucleotides plus taxol after castration in the Shionogi tumor model , 2000, International journal of cancer.

[54]  Schr,et al.  Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. , 1994, The American journal of pathology.

[55]  F. S. French,et al.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.

[56]  H. Perlman,et al.  Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. , 1995, Cancer research.

[57]  S. Yeh,et al.  Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[58]  J. Graff.  Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma , 2002, Expert opinion on therapeutic targets.

[59]  Desok Kim,et al.  Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. , 1998, Cancer research.

[60]  Barrack Er.  Androgen receptor mutations in prostate cancer. , 1996 .

[61]  M. Czuczman,et al.  Bcl-2 antisense therapy in B-cell malignant proliferative disorders , 2004, Current treatment options in oncology.

[62]  S. Inui,et al.  Cloning and Characterization of Androgen Receptor Coactivator, ARA55, in Human Prostate* , 1999, The Journal of Biological Chemistry.

[63]  K. Nath,et al.  Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. , 1998, Kidney international.

[64]  E. Bissonette,et al.  Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. , 2003, Cancer research.

[65]  J. Bartlett,et al.  Amplification of the androgen receptor gene in bone metastases from hormone‐refractory prostate cancer , 2002, The Journal of pathology.

[66]  H. Miyake,et al.  Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. , 2000, Cancer research.

[67]  D. Clemmons,et al.  Insulin-like growth factors and their binding proteins: biological actions. , 1995, Endocrine reviews.

[68]  A. Rademaker,et al.  Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[69]  G. Wilding,et al.  Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[70]  D. Peehl,et al.  Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. , 1994, The Journal of endocrinology.

[71]  H. Klocker,et al.  Synergistic activation of androgen receptor by androgen and luteinizing hormone‐releasing hormone in prostatic carcinoma cells , 1997, The Prostate.

[72]  M. Gleave,et al.  Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. , 2000, Journal of the National Cancer Institute.

[73]  D. Neal,et al.  Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer , 2001, British Journal of Cancer.

[74]  J. Welsh,et al.  Active cell death in hormone-dependent tissues , 1992, Cancer and Metastasis Reviews.

[75]  Honglin Zhou,et al.  Akt Regulates Cell Survival and Apoptosis at a Postmitochondrial Level , 2000, The Journal of cell biology.

[76]  O. Cussenot,et al.  Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. , 2001, Cancer research.

[77]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[78]  S. Groshen,et al.  Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. , 2001, The Journal of urology.

[79]  C. Olsson,et al.  SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. , 1991, Kidney international.

[80]  H. Klocker,et al.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. , 1993, Molecular endocrinology.

[81]  D. Bostwick,et al.  Independent origin of multiple foci of prostatic intraepithelial neoplasia , 1998, Cancer.

[82]  M. Tenniswood,et al.  Androgen‐repressed messages in the rat ventral prostate , 1986, The Prostate.

[83]  M. Namiki,et al.  ADRENAL STEROIDS IN HUMAN PROSTATIC CANCER CELL LINES , 2001, Archives of andrology.

[84]  C. Petito,et al.  Overexpression of clusterin in human breast carcinoma. , 2000, The American journal of pathology.

[85]  P. Cohen,et al.  Prostatic involution in men taking finasteride is associated with elevated levels of insulin‐like growth factor‐binding proteins (IGFBPs)‐2, ‐4, and ‐5 , 2000, The Prostate.

[86]  G. Jenster,et al.  The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[87]  E Mahlamäki,et al.  Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. , 1999, Journal of the National Cancer Institute.